# Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine

> **NCT02868073** · PHASE1 · COMPLETED · sponsor: **Vaxart** · enrollment: 66 (actual)

## Conditions studied

- Norovirus Gastroenteritis

## Interventions

- **BIOLOGICAL:** VXA-G1.1-NN (high dose) Oral Vaccine Tablet
- **OTHER:** VXA Placebo Tablets
- **BIOLOGICAL:** VXA-G1.1-NN (low dose) Oral Vaccine Tablet

## Key facts

- **NCT ID:** NCT02868073
- **Lead sponsor:** Vaxart
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-29
- **Primary completion:** 2016-10-05
- **Final completion:** 2017-10-01
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2018-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02868073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02868073, "Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02868073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*